Table 3 Results of network meta-analysis of the incidence of SAEs

1.33 (0.52,3.42) ⊕⊕⊝⊝low2,4

Ambrisentan

1.18 (0.33,4.22) ⊕⊕⊝⊝low2,4

0.89 (0.29,2.69) ⊕⊕⊝⊝low2,4

Pamrevlumab

1.63 (0.58,4.56) ⊕⊕⊝⊝low2,4

1.23 (0.54,2.77) ⊕⊕⊝⊝low2,4

1.38 (0.42,4.52) ⊕⊕⊕⊝moderate4

N-acetylcysteine

1.96 (0.82,4.71) ⊕⊕⊝⊝low2,4

1.48 (0.80,2.72) ⊕⊕⊝⊝low2,4

1.67 (0.58,4.78) ⊕⊕⊝⊝low2,4

1.21 (0.58,2.51) ⊕⊕⊝⊝low2,4

Simtuzumab

2.09 (0.90,4.83) ⊕⊕⊝⊝low2,4

1.57 (0.90,2.75) ⊕⊕⊝⊝low2,4

1.77 (0.63,4.93) ⊕⊕⊕⊝moderate4

1.28 (0.64,2.56) ⊕⊕⊕⊝moderate4

1.06 (0.69,1.64) ⊕⊕⊝⊝low2,4

Pirfenidone

2.09 (0.94,4.66) ⊕⊕⊕⊝moderate2

1.57 (0.96,2.59) ⊕⊕⊕⊝moderate2

1.78 (0.66,4.80) ⊕⊕⊕⊕high

1.28 (0.67,2.45) ⊕⊕⊕⊕high

1.07 (0.75,1.51) ⊕⊕⊕⊝moderate2

1.00 (0.78,1.29) ⊕⊕⊕⊕high

Placebo

2.21 (0.72,6.74) ⊕⊕⊝⊝low2,4

1.66 (0.66,4.18) ⊕⊕⊝⊝low2,4

1.87 (0.53,6.62) ⊕⊕⊕⊝moderate4

1.36 (0.49,3.72) ⊕⊕⊕⊝moderate4

1.12 (0.48,2.64) ⊕⊕⊝⊝low2,4

1.06 (0.47,2.40) ⊕⊕⊕⊝moderate4

1.06 (0.49,2.29) ⊕⊕⊕⊕high

Imatinib

2.18 (0.94,5.01) ⊕⊕⊝⊝low2,4

1.64 (0.94,2.84) ⊕⊕⊝⊝low2,4

1.85 (0.67,5.12) ⊕⊕⊕⊝moderate4

1.34 (0.67,2.65) ⊕⊕⊕⊝moderate4

1.11 (0.73,1.69) ⊕⊕⊝⊝low2,4

1.04 (0.74,1.47) ⊕⊕⊕⊝moderate4

1.04 (0.82,1.31) ⊕⊕⊕⊕high

0.98 (0.44,2.22) ⊕⊕⊕⊝moderate4

Nintedanib

2.42 (0.77,7.53) ⊕⊕⊝⊝low2,4

1.82 (0.70,4.69) ⊕⊕⊝⊝low2,4

2.05 (0.57,7.37) ⊕⊕⊕⊝moderate4

1.48 (0.53,4.17) ⊕⊕⊕⊝moderate4

1.23 (0.51,2.96) ⊕⊕⊝⊝low2,4

1.16 (0.50,2.70) ⊕⊕⊕⊝moderate4

1.15 (0.51,2.59) ⊕⊕⊕⊕high

1.09 (0.36,3.35) ⊕⊕⊕⊝moderate4

1.11 (0.48,2.58) ⊕⊕⊕⊝moderate4

Sildenafil

2.38 (0.84,6.73) ⊕⊕⊝⊝low2,4

1.79 (0.78,4.11) ⊕⊕⊝⊝low2,4

2.02 (0.61,6.67) ⊕⊕⊕⊝moderate4

1.46 (0.58,3.69) ⊕⊕⊕⊝moderate4

1.21 (0.57,2.57) ⊕⊕⊝⊝low2,4

1.14 (0.56,2.32) ⊕⊕⊕⊝moderate4

1.14 (0.58,2.21) ⊕⊕⊕⊕high

1.08 (0.39,2.99) ⊕⊕⊕⊝moderate4

1.09 (0.54,2.21) ⊕⊕⊕⊝moderate4

0.98 (0.35,2.80) ⊕⊕⊕⊝moderate4

Macitentan

2.83 (0.60,13.35) ⊕⊕⊝⊝low2,4

2.13 (0.52,8.80) ⊕⊕⊝⊝low2,4

2.40 (0.46,12.62) ⊕⊕⊕⊝moderate4

1.74 (0.40,7.61) ⊕⊕⊕⊝moderate4

1.44 (0.36,5.69) ⊕⊕⊝⊝low2,4

1.36 (0.35,5.25) ⊕⊕⊕⊝moderate4

1.35 (0.36,5.10) ⊕⊕⊕⊕high

1.28 (0.28,5.97) ⊕⊕⊕⊝moderate4

1.30 (0.34,5.01) ⊕⊕⊕⊝moderate4

1.17 (0.25,5.55) ⊕⊕⊕⊝moderate4

1.19 (0.27,5.25) ⊕⊕⊕⊝moderate4

PRM151

2.49 (1.06,5.89) ⊕⊕⊝⊝low2,4

1.88 (1.04,3.38) ⊕⊕⊝⊝low2,4

2.12 (0.75,6.00) ⊕⊕⊕⊝moderate4

1.53 (0.75,3.13) ⊕⊕⊕⊝moderate4

1.27 (0.79,2.03) ⊕⊕⊝⊝low2,4

1.20 (0.80,1.79) ⊕⊕⊕⊝moderate4

1.19 (0.87,1.63) ⊕⊕⊕⊕high

1.13 (0.49,2.61) ⊕⊕⊕⊝moderate4

1.15 (0.78,1.69) ⊕⊕⊕⊝moderate4

1.03 (0.43,2.46) ⊕⊕⊕⊝moderate4

1.05 (0.50,2.18) ⊕⊕⊕⊝moderate4

0.88 (0.23,3.45) ⊕⊕⊕⊝moderate4

Bosentan

16.75 (1.06,263.92) ⊕⊕⊝⊝low2,4

12.59 (0.86,184.67) ⊕⊕⊝⊝low2,4

14.21 (0.85,238.28) ⊕⊕⊕⊝moderate4

10.28 (0.68,155.45) ⊕⊕⊕⊝moderate4

8.52 (0.60,122.08) ⊕⊕⊝⊝low2,4

8.03 (0.57,113.76) ⊕⊕⊕⊝moderate4

8.00 (0.57,111.96) ⊕⊕⊕⊕high

7.58 (0.48,118.62) ⊕⊕⊕⊝moderate4

7.70 (0.54,108.87) ⊕⊕⊕⊝moderate4

6.93 (0.44,109.50) ⊕⊕⊕⊝moderate4

7.04 (0.46,106.96) ⊕⊕⊕⊝moderate4

5.92 (0.31,113.49) ⊕⊕⊕⊝moderate4

6.71 (0.47,95.69) ⊕⊕⊕⊝moderate4

GLPG1690